微阵列分析对胎儿迷走右锁骨下动脉无附加价值:268例妊娠描述及系统文献综述
该研究回顾性分析以色列卫生部2013至2017年因胎儿迷走右锁骨下动脉(ARSA)行侵入性检测和染色体微阵列分析(CMA)的妊娠,孤立性ARSA 246例中临床显著CMA发现1例(0.4%,21三体),与低风险对照2752例无显著差异(P=0.1574);非孤立性ARSA 22例中21三体1例(4.5%),与对照相比相对危险度5.5(95%CI 0.8-37.6)。文献综述纳入13篇额外论文333例孤立性ARSA,合并579例中21三体13例(2.2%),无22q11.2微缺失病例。结论认为孤立性ARSA可能更宜作为21三体的软指标,而非常规侵入性产前检测指征。
要点
- 孤立性ARSA中CMA临床显著异常率0.4%(1/246,21三体),与低风险对照无显著差异(P=0.1574)。
- 非孤立性ARSA中21三体4.5%(1/22),与对照相比RR 5.5(95%CI 0.8-37.6),未达统计学显著。
- 文献合并579例孤立性ARSA中21三体2.2%(13例),无22q11.2微缺失病例。
核心结论
- 非孤立性ARSA与21三体之间可能存在关联,而孤立性ARSA可能更宜作为21三体的软指标,而非常规侵入性产前检测的指征。
研究设计与样本
- 回顾性研究,数据来自以色列卫生部计算机数据库,纳入2013至2017年因超声诊断胎儿ARSA而转诊行侵入性检测和CMA的妊娠(孤立性ARSA 246例、非孤立性ARSA 22例),对照为2752例超声和血清筛查正常的低风险妊娠;另在PubMed检索至2018年2月的英文原始研究,纳入描述孤立性ARSA胎儿微观和亚微观异常频率与性质的文献。
诊断标准与关键数值
- 孤立性ARSA 246例中临床显著CMA发现1例(0.4%,21三体),与对照人群相比P=0.1574;非孤立性ARSA 22例中21三体1例(4.5%),与对照相比相对危险度5.5(95%CI 0.8-37.6);文献检索额外纳入13篇论文共333例孤立性ARSA,合并579例中21三体13例(2.2%),无22q11.2微缺失病例。
临床应用与阅片要点
- 作者认为孤立性ARSA可能更宜作为21三体的软指标,而非常规侵入性产前检测的指征。
局限性
- 非孤立性ARSA与对照比较的相对危险度95%CI宽(0.8-37.6)。
- 原文结论提出孤立性ARSA可能更宜作为软指标而非常规侵入性检测指征,措辞为「might better serve」,未给出确定性推荐。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: Fetal aberrant right subclavian artery (ARSA) is a relatively common sonographic finding. Several studies have reported a significant association between ARSA and Down syndrome, as well as 22q11.2 microdeletion. The objective of this study was to assess the risk of abnormal chromosomal microarray analysis (CMA) findings in a large cohort of pregnancies with fetal ARSA as an isolated, as well as a non-isolated, sonographic anomaly. A secondary objective was to review the literature, examining the frequency of chromosomal microarray aberrations in fetuses with isolated ARSA.
METHODS: Data from all pregnancies referred for invasive testing and CMA due to sonographic diagnosis of fetal ARSA, between 2013 and 2017, were obtained retrospectively from the computerized database of the Israeli Ministry of Health. The rate of clinically significant CMA findings in these fetuses was compared to that in a local control population of 2752 low-risk pregnancies with normal ultrasound and serum screening results. In addition, a literature search was conducted in PubMed, from inception to February 2018, of original studies in the English language describing the frequency and nature of microscopic and submicroscopic aberrations in fetuses with isolated ARSA.
RESULTS: Of 246 pregnancies with isolated ARSA that underwent CMA analysis, a clinically significant finding was detected in one (0.4%) pregnancy (trisomy 21). This rate did not differ significantly from that in the control population (P = 0.1574). Of 22 fetuses with non-isolated ARSA, one (4.5%) additional case of trisomy 21 was noted. The frequency of trisomy 21 in this cohort also did not differ from that in the control population (relative risk, 5.5 (95% CI, 0.8-37.6)). The literature search yielded 13 additional relevant papers, encompassing 333 cases of isolated ARSA. Of 579 cases overall (including those of the present study), 13 (2.2%) cases of trisomy 21 were detected, with no cases of 22q11.2 microdeletion.
CONCLUSION: While an association may exist between non-isolated ARSA and Down syndrome, isolated ARSA might better serve as a soft marker for Down syndrome, rather than a routine indication for invasive prenatal testing. Copyright © 2018 ISUOG. Published by John Wiley & Sons Ltd.
引用
- Sagi-Dain L, Singer A, Josefsberg S, et al. Microarray analysis has no additional value in fetal aberrant right subclavian artery: description of 268 pregnancies and systematic literature review. Ultrasound Obstet Gynecol. 2019. PMID: 30584678. doi:10.1002/uog.20208
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。